United States & European Biosimilar Insulin Market Access Report 2017

Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Biosimilar Insulin Market Access" report to their offering.

Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.

The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants Toujeo and Tresiba.

More aggressive payers are excluding branded insulin products in favor of the less expensive biosimilar, forcing switches in existing patient populations.

As such, manufacturers of branded insulin products will need to offer deeper discounts to remain on payers' formularies and contracts.

Key Topics Covered:

1. EXECUTIVE SUMMARY

2. US

• Insights and strategic recommendations
• US payers are adopting a wait-and-see approach for biosimilar Basaglar
• Bibliography

3. FIVE MAJOR EU MARKETS

• Insights and strategic recommendations
• Uptake of biosimilar insulin varies across EU markets as the EMA does not determine interchangeability
• Physicians and payers have varying views on the interchangeability of biosimilar insulins, but see large opportunities to reduce costs
• Payers use biosimilars to pressure originators on pricing
• Pharmacies continue to procure both biosimilars and originators; dynamic pricing environment observed
• Patient switching requires significant discounts of at least 30%
• Given attractive discounts, payers will use a variety of market access tools to drive Basaglar's uptake
• Bibliography

4. METHODOLOGY

For more information about this report visit http://www.researchandmarkets.com/research/5k4v4m/biosimilar

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Immune Disorders Drugs, Biosimilars and Biosuperiors